BridgeMD
New treatment option for Pancreatic Ductal Adenocarcinoma
Official title Pancreatic Cancer Screening in a Population at High Risk
ClinicalTrials.gov ID: NCT06330441
What this study is testing
- What it's testing
- Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- willing to participate in the study
- age 18+
- arms specific criteria: A:
- chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis
- age 50+ B1:
You likely can't join if
- Inability to undergo radical curative surgery for a pancreatic tumor.
- Inability to undergo scheduled imaging examinations.
- Incurable malignant cancer.
See the full eligibility criteria
- willing to participate in the study
- age 18+
- arms specific criteria: A:
- chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis
- age 50+ B1:
- confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
- familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
- confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack B2:
- confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome...
- at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)
- age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first C:
- positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context
- age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members
- Inability to undergo radical curative surgery for a pancreatic tumor.
- Inability to undergo scheduled imaging examinations.
- Incurable malignant cancer.
The study team makes the final eligibility decision.
Where it's taking place
- Brno, Czechia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brno, Czechia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.